ELTX — Elicio Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1601485 ·
Last close
$1.43
Market Cap
$40.48M
52W High
$16.00
52W Low
$1.25
ADV30
309,150
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -8,452,000 | -7,979,000 | 39,596,000 | 30,900,000 | 20,745,000 |
| Jun 2026 | 0 | — | -10,429,000 | -8,217,000 | 31,330,000 | 23,480,000 | 23,393,000 |
| Mar 2026 | 0 | — | -10,602,000 | -11,823,000 | 22,689,000 | 14,948,000 | 24,126,000 |
| Dec 2025 | 0 | — | -8,842,000 | -7,718,000 | 25,862,000 | 18,563,000 | 24,226,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-37,693,000
Investing CF
$-16,000
Financing CF
$38,972,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.34
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-253,712,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-36,261,000
Pretax Income TTM
$-37,841,000
Interest Exp TTM
$1,580,000
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -37,299,000 | -39,571,000 | 25,862,000 | 24,226,000 | 1,636,000 | -36,952,000 |
| Dec 2024 | 0 | -44,986,000 | -51,898,000 | 28,178,000 | 39,490,000 | -11,312,000 | -37,068,000 |
| Dec 2023 | 0 | -35,745,000 | -35,195,000 | 27,146,000 | 15,773,000 | 11,373,000 | -32,694,000 |
| Dec 2022 | 0 | -23,733,000 | -28,208,000 | 22,664,000 | 124,809,000 | -102,145,000 | -22,179,000 |
TTM Snapshot
Revenues TTM
$29,436,000
NetIncome TTM
$-37,841,000
OpCashFlow TTM
—
Assets (Latest)
$31,330,000
Forward EPS
$-1.69
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.59 · call volume: 361 · put volume: 0
Expected Move to 2027-05-21:
±$1.52
(95.60%) —
implied range
$0.07 –
$3.11
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PLRX | PLIANT THERAPEUTICS, INC. | $40.93M | $0.66 | — |
| DWTX | Dogwood Therapeutics, Inc. | $41.29M | $1.08 | — |
| TLPH | TALPHERA, INC. | $41.61M | $0.80 | — |
| ALDX | Aldeyra Therapeutics, Inc. | $41.88M | $0.69 | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $42.45M | $1.35 | — |
News headlines (Yahoo Finance, 1h cache)
Elicio Therapeutics: Q3 Earnings Snapshot
2026-11-05 21:15 · Yahoo
Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-05 21:01 · Yahoo
Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
2026-11-04 13:00 · Yahoo
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
2026-10-29 13:00 · Yahoo
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
2026-10-23 13:00 · Yahoo
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
2026-09-24 12:00 · Yahoo
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-31 12:00 · Yahoo
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
2026-08-24 12:00 · Yahoo
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
2026-07-02 04:25 · Yahoo
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
2026-06-29 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.